Isentress launched in Japan
This article was originally published in Scrip
Executive Summary
Merck & Cohas launched its first-in-class integrase inhibitor for HIV Isentress (raltegravir) in Japan through its local subsidiaryBanyu. The product, which has orphan status, is indicated in combination with other antiretrovirals in adults who have already received treatment, and is reimbursed at ¥1,510.40 ($14.0) per 400mg tablet. The standard dose is one tablet twice a day, which does not have to be taken with food. Isentress was approved in the US last October and in the EU at the beginning of this year.